Impact of Linagliptin vs Glimepiride on Glycemic Variability in Subjects with Type 2 Diabetes Mellitus at High Cardiovascular Risk: a substudy of the CAROLINA trial [SUBSTUDY OF 700191596]

Trial Profile

Impact of Linagliptin vs Glimepiride on Glycemic Variability in Subjects with Type 2 Diabetes Mellitus at High Cardiovascular Risk: a substudy of the CAROLINA trial [SUBSTUDY OF 700191596]

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 08 Jun 2016

At a glance

  • Drugs Linagliptin (Primary) ; Glimepiride
  • Indications Cardiovascular disorders; Type 2 diabetes mellitus
  • Focus Registrational; Therapeutic Use
  • Acronyms CAROLINA CGM; Carolina Sub-study 1
  • Sponsors Boehringer Ingelheim Pharmaceuticals
  • Most Recent Events

    • 09 Jun 2015 Results for baseline characteristics presented at the 75th Annual Scientific Sessions of the American Diabetes Association.
    • 31 Jan 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top